Format

Send to

Choose Destination
Arch Phys Med Rehabil. 2018 Feb;99(2):299-305. doi: 10.1016/j.apmr.2017.09.001. Epub 2017 Sep 9.

Randomized Trial of Clitoral Vacuum Suction Versus Vibratory Stimulation in Neurogenic Female Orgasmic Dysfunction.

Author information

1
Department of Physical Medicine and Rehabilitation, University of Alabama at Birmingham School of Medicine, Birmingham, AL; Birmingham VA Medical Center, Birmingham, AL; Department of Physical Medicine and Rehabilitation, Harvard School of Medicine, Boston, MA. Electronic address: spinalcordmd@live.com.
2
Department of Neurology, University of Alabama at Birmingham School of Medicine, Birmingham, AL.
3
Birmingham VA Medical Center, Birmingham, AL.
4
Dignify Therapeutics, Research Triangle Park, NC; Department of Urology, School of Medicine and MOPH Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC.
5
New England Research Institute, Watertown, MA.

Abstract

OBJECTIVE:

To examine the safety and efficacy of using a clitoral vacuum suction device (CVSD) versus vibratory stimulation (V) to treat orgasmic dysfunction in women with multiple sclerosis (MS) or spinal cord injury (SCI).

DESIGN:

Randomized clinical trial.

SETTING:

Two academic medical centers.

PARTICIPANTS:

Women (N=31) including 20 with MS and 11 with SCI.

INTERVENTION:

A 12-week trial of the use of a CVSD versus V.

MAIN OUTCOME MEASURES:

Female Sexual Function Inventory (FSFI) and Female Sexual Distress Scale (FSDS).

RESULTS:

Twenty-three women (18 MS, 5 SCI) completed the study including 13 of 16 randomized to CVSD and 10 of 15 randomized to V. There was a statistically significant increase in total FSFI score (P=.011), desire (P=.009), arousal (P=.009), lubrication (P=.008), orgasm (P=.012), and satisfaction (P=.049), and a significant decrease in distress as measured by FSDS (P=.020) in subjects using the CVSD. In subjects who used V, there was a statistically significant increase in the orgasm subscale of the FSFI (P=.028). Subjects using the CVSD maintained improvements 4 weeks after treatment.

CONCLUSIONS:

CVSD is safe and overall efficacious to treat female neurogenic sexual dysfunction related to MS and SCI. V is also safe and efficacious for female neurogenic orgasmic dysfunction; however, results were limited to the active treatment period. Because of ease of access and cost, clinicians can consider use of V for women with MS or SCI with orgasmic dysfunction. CVSD is recommended for women with multiple sexual dysfunctions or for whom V is ineffective.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00142714.

KEYWORDS:

Arousal; Female; Multiple sclerosis; Quality of life; Reflex; Rehabilitation; Spinal cord injuries

PMID:
28899827
DOI:
10.1016/j.apmr.2017.09.001
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center